Ambrx Biopharma, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ambrx Biopharma, Inc.
With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
CEO Joaquin Duato said J&J is agnostic on size when it comes to business development but has generally found more value creation in earlier-stage deals.
To emerge from a wilderness period or biotech winter where generalist investors shun the sector, biotech’s good news needs to outweigh the bad and be attractively priced. We may not be there yet.
- Drug Delivery
- Drug Discovery Technologies
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Ambrx, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.